Compare Stocks: ADCT, CTMX, VALN, and SGMT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADCT ADC Therapeutics	$1.13 +4.2%	$1.14	$0.78 ▼ $4.98	$144.27M	1.86	1.32 million shs	1.32 million shs
CTMX CytomX Therapeutics	$2.56 -2.7%	$3.21	$2.55 ▼ $8.21	$573.07M	2.21	3.97 million shs	2.62 million shs
SGMT Sagimet Biosciences	$9.14 -2.5%	$9.82	$4.50 ▼ $11.45	$582.43M	3.46	1.36 million shs	1.71 million shs
VALN Valneva	$5.74 -2.7%	$6.22	$4.75 ▼ $12.18	$544.65M	1.53	23,544 shs	39,844 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADCT ADC Therapeutics	+4.65%	-11.00%	-15.09%	-6.64%	-71.84%
CTMX CytomX Therapeutics	-2.66%	-5.19%	-31.18%	-32.98%	-23.58%
SGMT Sagimet Biosciences	-2.45%	-1.08%	-16.83%	+20.11%	+30.95%
VALN Valneva	-2.71%	-6.51%	-19.38%	+9.96%	-50.39%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADCT ADC Therapeutics	$1.13 +4.2%	$1.14	$0.78 ▼ $4.98	$144.27M	1.86	1.32 million shs	1.32 million shs
CTMX CytomX Therapeutics	$2.56 -2.7%	$3.21	$2.55 ▼ $8.21	$573.07M	2.21	3.97 million shs	2.62 million shs
SGMT Sagimet Biosciences	$9.14 -2.5%	$9.82	$4.50 ▼ $11.45	$582.43M	3.46	1.36 million shs	1.71 million shs
VALN Valneva	$5.74 -2.7%	$6.22	$4.75 ▼ $12.18	$544.65M	1.53	23,544 shs	39,844 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADCT ADC Therapeutics	+4.65%	-11.00%	-15.09%	-6.64%	-71.84%
CTMX CytomX Therapeutics	-2.66%	-5.19%	-31.18%	-32.98%	-23.58%
SGMT Sagimet Biosciences	-2.45%	-1.08%	-16.83%	+20.11%	+30.95%
VALN Valneva	-2.71%	-6.51%	-19.38%	+9.96%	-50.39%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADCT ADC Therapeutics	2.33	Hold	$5.00	344.44% Upside
CTMX CytomX Therapeutics	2.83	Moderate Buy	$11.90	364.84% Upside
SGMT Sagimet Biosciences	2.58	Moderate Buy	$26.63	191.41% Upside
VALN Valneva	1.67	Reduce	$9.30	62.02% Upside

Current Analyst Ratings Breakdown

Latest ADCT, CTMX, VALN, and SGMT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/2/2026	SGMT Sagimet Biosciences	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$25.00 ➝ $26.00
10/1/2026	SGMT Sagimet Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
10/1/2026	SGMT Sagimet Biosciences	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
10/1/2026	SGMT Sagimet Biosciences	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$33.00 ➝ $38.00
10/1/2026	SGMT Sagimet Biosciences	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Market Outperform	$29.00 ➝ $27.00
9/28/2026	SGMT Sagimet Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$29.00
9/24/2026	SGMT Sagimet Biosciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Sell	$7.00
9/24/2026	SGMT Sagimet Biosciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Sell	$7.00
9/14/2026	VALN Valneva	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
9/11/2026	CTMX CytomX Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
9/9/2026	SGMT Sagimet Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$10.71

(Data available from 10/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADCT ADC Therapeutics	$79.58M	1.80	N/A	N/A	($1.50) per share	-0.75
CTMX CytomX Therapeutics	$18.30M	30.48	N/A	N/A	$0.58 per share	4.41
SGMT Sagimet Biosciences	N/A	N/A	N/A	N/A	$3.42 per share	N/A
VALN Valneva	$142.94M	3.81	N/A	N/A	$1.39 per share	4.13

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADCT ADC Therapeutics	-$142.62M	-$0.66	N/A	N/A	N/A	-121.77%	N/A	-32.74%	11/10/2026 (Estimated)
CTMX CytomX Therapeutics	-$17.37M	-$0.50	N/A	N/A	N/A	-435.21%	-38.46%	-30.33%	11/5/2026 (Estimated)
SGMT Sagimet Biosciences	-$51.04M	-$1.28	N/A	N/A	N/A	N/A	-31.96%	-30.57%	11/12/2026 (Estimated)
VALN Valneva	-$130.33M	-$2.11	N/A	13.05	N/A	-110.33%	-153.20%	-39.50%	11/19/2026 (Estimated)

Latest ADCT, CTMX, VALN, and SGMT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	VALN Valneva	-$0.1886	-$0.40	-$0.2114	-$0.38	$44.17 million	$39.37 million
8/13/2026	Q2 2026	ADCT ADC Therapeutics	-$0.2160	-$0.11	+$0.1060	-$0.11	$18.89 million	$19.25 million
8/11/2026	Q2 2026	SGMT Sagimet Biosciences	-$0.2510	-$0.26	-$0.0090	-$0.26	N/A	N/A
8/6/2026	Q2 2026	CTMX CytomX Therapeutics	-$0.0771	-$0.09	-$0.0129	-$0.09	$12.39 million	$1.42 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADCT ADC Therapeutics	N/A	N/A	N/A	N/A	N/A
CTMX CytomX Therapeutics	N/A	N/A	N/A	N/A	N/A
SGMT Sagimet Biosciences	N/A	N/A	N/A	N/A	N/A
VALN Valneva	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADCT ADC Therapeutics	N/A	3.03	2.97
CTMX CytomX Therapeutics	N/A	9.36	9.36
SGMT Sagimet Biosciences	N/A	45.03	45.02
VALN Valneva	2.04	2.16	1.69

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADCT ADC Therapeutics	41.10%
CTMX CytomX Therapeutics	67.77%
SGMT Sagimet Biosciences	87.86%
VALN Valneva	11.39%

Insider Ownership

Company	Insider Ownership
ADCT ADC Therapeutics	5.10%
CTMX CytomX Therapeutics	3.80%
SGMT Sagimet Biosciences	11.50%
VALN Valneva	14.91%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADCT ADC Therapeutics	191	127.67 million	121.16 million	Optionable
CTMX CytomX Therapeutics	69	217.90 million	209.62 million	Optionable
SGMT Sagimet Biosciences	16	62.16 million	55.01 million	Optionable
VALN Valneva	674	94.89 million	80.74 million	Not Optionable

ADCT, CTMX, VALN, and SGMT Headlines

Recent News About These Companies

Journée en forte hausse pour Valneva SE

September 28, 2026 | boursier.comB

Septerna (NASDAQ:SEPN) vs. Valneva (NASDAQ:VALN) Financial Review

September 26, 2026 | americanbankingnews.com

Analyzing Valneva (NASDAQ:VALN) and Septerna (NASDAQ:SEPN)

September 24, 2026 | defenseworld.netD

Football fundraiser collects £2k for Livingston charity Team Jak Foundation

September 22, 2026 | msn.com

Valneva's Lyme Shot Nears EU Verdict as Pipeline Readouts and Cost Cuts Converge

September 21, 2026 | ad-hoc-news.deA

Pfizer (PFE), Valneva (VALN) Lyme Vaccine Moves to EMA Review Despite Phase 3 Caveat

September 15, 2026 | insidermonkey.com

Valneva Aktie: Umsatz bricht um 33 Prozent ein

September 9, 2026 | boerse-express.comB

Valneva Aktie: Verkauf von Nantes vereinbart

September 6, 2026 | boerse-express.comB

Potential Moderna-style share surge? Takeover candidates Evotec, Valneva and Vidac Pharma in focus — analysts bullish

September 1, 2026 | msn.com

Valneva's Property Sale Buys Breathing Room as Travel-Vaccine Demand Sours

August 30, 2026 | ad-hoc-news.deA

Valneva's High-Wire Act: Can Cost Cuts and a Pivotal EMA Review Bridge the Gap to 2026?

August 29, 2026 | ad-hoc-news.deA

Answers to 3 questions about a potential Lyme vaccine

August 28, 2026 | msn.com

Valneva's Regulatory Tailwind Collides With a Deepening Loss Profile

August 24, 2026 | ad-hoc-news.deA

Valneva's Analyst Divide Widens as EMA Review Puts Statistical Questions in the Spotlight

August 20, 2026 | ad-hoc-news.deA

Valneva (VALN) Q2 2026 Earnings Call Transcript

August 20, 2026 | finance.yahoo.com

EMA validates marketing authorisation application of Pfizer & Valneva’s PF-07307405, a 6-valent OspA-based Lyme disease vaccine

August 17, 2026 | pharmabiz.comP

EMA validates Pfizer and Valneva’s Lyme disease vaccine

August 17, 2026 | msn.com

Pfizer, Valneva Lyme vaccine starts review in Europe

August 15, 2026 | pharmaphorum.comP

Valneva Shares Climb After Lyme Disease Vaccine Receives EMA Application Acceptance

August 15, 2026 | marketwatch.com

Update: Valneva Shares Gain as Lyme Vaccine Candidate Gets EMA Review

August 15, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADCT, CTMX, VALN, and SGMT Company Descriptions

ADC Therapeutics NYSE:ADCT

$1.12 +0.05 (+4.17%)

Closing price 10/2/2026 03:59 PM Eastern

Extended Trading

$1.14 +0.02 (+1.51%)

As of 10/2/2026 07:56 PM Eastern

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

CytomX Therapeutics NASDAQ:CTMX

$2.56 -0.07 (-2.66%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$2.60 +0.04 (+1.37%)

As of 10/2/2026 07:30 PM Eastern

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Sagimet Biosciences NASDAQ:SGMT

$9.14 -0.23 (-2.45%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$9.23 +0.09 (+1.02%)

As of 10/2/2026 07:55 PM Eastern

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

Valneva NASDAQ:VALN

$5.74 -0.16 (-2.71%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$5.78 +0.04 (+0.70%)

As of 10/2/2026 04:10 PM Eastern

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ADCT, CTMX, VALN, and SGMT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ADCT, CTMX, VALN, and SGMT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ADCT, CTMX, VALN, and SGMT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADCT, CTMX, VALN, and SGMT Company Descriptions

ADC Therapeutics NYSE:ADCT

CytomX Therapeutics NASDAQ:CTMX

Sagimet Biosciences NASDAQ:SGMT

Valneva NASDAQ:VALN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ADCT, CTMX, VALN, and SGMT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ADCT, CTMX, VALN, and SGMT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ADCT, CTMX, VALN, and SGMT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADCT, CTMX, VALN, and SGMT Company Descriptions

ADC Therapeutics NYSE:ADCT

CytomX Therapeutics NASDAQ:CTMX

Sagimet Biosciences NASDAQ:SGMT

Valneva NASDAQ:VALN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools